JP2012513443A5 - - Google Patents

Info

Publication number

JP2012513443A5

JP2012513443A5 JP2011542807A JP2011542807A JP2012513443A5 JP 2012513443 A5 JP2012513443 A5 JP 2012513443A5 JP 2011542807 A JP2011542807 A JP 2011542807A JP 2011542807 A JP2011542807 A JP 2011542807A JP 2012513443 A5 JP2012513443 A5 JP 2012513443A5

Authority

JP

Japan

Prior art keywords

phenyl

compound

alkyl

formula

salt

Prior art date

2009-12-21

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 18
• 150000003839 salts Chemical class 0.000 claims description 17
• 238000011282 treatment Methods 0.000 claims description 5
• 201000010099 disease Diseases 0.000 claims description 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
• 150000002148 esters Chemical class 0.000 claims 11
• -1 phenyl-isopropyl Chemical group 0.000 claims 11
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
• 229910052739 hydrogen Inorganic materials 0.000 claims 5
• 239000001257 hydrogen Substances 0.000 claims 5
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
• 208000006386 Bone Resorption Diseases 0.000 claims 3
• 230000024279 bone resorption Effects 0.000 claims 3
• 239000008194 pharmaceutical composition Substances 0.000 claims 3
• 125000004344 phenylpropyl group Chemical group 0.000 claims 3
• 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
• 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
• 125000004093 cyano group Chemical group *C#N 0.000 claims 2
• 125000001475 halogen functional group Chemical group 0.000 claims 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
• 238000000034 method Methods 0.000 claims 2
• 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
• 125000001424 substituent group Chemical group 0.000 claims 2
• 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 claims 1
• 241001465754 Metazoa Species 0.000 claims 1
• 208000007932 Progeria Diseases 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 150000002431 hydrogen Chemical class 0.000 claims 1
• 125000003884 phenylalkyl group Chemical group 0.000 claims 1
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1
• 230000037396 body weight Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000000694 effects Effects 0.000 description 1
• 238000011866 long-term treatment Methods 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1